Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603275 · ClinicalTrials.gov registry record
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry
A clinical trial, sponsored by Bayer.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03603275 is a clinical trial that was terminated before completion, run by Bayer. The registered enrollment target is 3 participants.
The verdict
NCT03603275 was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.
Interventions
- DRUG New FVIII products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-06 |
| Est. Completion | 2020-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603275
The ClinicalTrials.gov registry entry for NCT03603275 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which New FVIII products is the first listed.
NCT03603275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03603275 about?
NCT03603275 is a clinical study titled "Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry". This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, re...
What is the current status of trial NCT03603275?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2018-08-06. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03603275?
The interventions under investigation include: New FVIII products (DRUG).
Who is sponsoring clinical trial NCT03603275?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.